Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PEN 
Penumbra Inc (PEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: PEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $310.88
1 Year Target Price $310.88
| 12 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.32% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.69B USD | Price to earnings Ratio 65.75 | 1Y Target Price 310.88 |
Price to earnings Ratio 65.75 | 1Y Target Price 310.88 | ||
Volume (30-day avg) 18 | Beta 0.4 | 52 Weeks Range 184.19 - 310.00 | Updated Date 08/13/2025 |
52 Weeks Range 184.19 - 310.00 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When - | Estimate 0.83 | Actual 0.86 |
Profitability
Profit Margin 11.54% | Operating Margin (TTM) 12.03% |
Management Effectiveness
Return on Assets (TTM) 6.2% | Return on Equity (TTM) 12.03% |
Valuation
Trailing PE 65.75 | Forward PE 70.42 | Enterprise Value 9489199512 | Price to Sales(TTM) 7.57 |
Enterprise Value 9489199512 | Price to Sales(TTM) 7.57 | ||
Enterprise Value to Revenue 7.41 | Enterprise Value to EBITDA 49 | Shares Outstanding 38999100 | Shares Floating 37807316 |
Shares Outstanding 38999100 | Shares Floating 37807316 | ||
Percent Insiders 3.67 | Percent Institutions 91.59 |
Upturn AI SWOT
Penumbra Inc
Company Overview
History and Background
Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California. The company is a global healthcare company focused on innovative therapies. Initially, it focused on stroke treatment but has since expanded into other vascular and neurovascular areas. Major milestones include FDA approvals for key products and significant growth in revenue and market share.
Core Business Areas
- Vascular: This segment focuses on products for treating peripheral vascular and venous diseases, including aspiration systems, catheters, and thrombectomy devices.
- Neurovascular: This segment offers products for treating neurovascular diseases, such as stroke and aneurysms, including aspiration systems, coils, and access devices.
Leadership and Structure
Adam Elsesser is the Chairman and CEO. The company operates with a functional organizational structure with departments specializing in R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Penumbra System: An aspiration-based thrombectomy system for stroke treatment and peripheral vascular procedures. Market share information is variable depending on the geography and specific application, but it is a significant competitor to Medtronic, Stryker, and Johnson & Johnson in thrombectomy. Exact market share numbers are difficult to obtain without dedicated market research resources. Estimated revenue is substantial, but not publicly broken out separately from overall company revenue.
- Indigo System: A percutaneous aspiration system used to remove thrombus and emboli from the peripheral vasculature. Competitors include Boston Scientific, Philips, and Medtronic. Market share information is variable depending on the geography and specific application. Estimated revenue is substantial, but not publicly broken out separately from overall company revenue.
Market Dynamics
Industry Overview
The medical device industry is characterized by high regulation, technological innovation, and increasing demand for minimally invasive procedures. Growth is driven by an aging population and advancements in medical technology.
Positioning
Penumbra is a key player in the interventional therapies market, specializing in neurovascular and vascular treatments. Its competitive advantage lies in its innovative product designs and focus on aspiration-based thrombectomy.
Total Addressable Market (TAM)
The total addressable market for neurovascular and vascular medical devices is estimated to be in the tens of billions of dollars globally. Penumbra is well-positioned to capture a significant portion of this TAM with its portfolio of innovative products and strong market presence.
Upturn SWOT Analysis
Strengths
- Innovative Product Portfolio
- Strong Brand Recognition
- Focus on Aspiration Technology
- Established Sales and Distribution Network
- Experienced Leadership Team
Weaknesses
- Product Recalls Impacting Reputation
- Reliance on a Limited Number of Key Products
- Exposure to Product Liability Claims
- Dependence on regulatory approvals
- Limited geographic diversification
Opportunities
- Expanding Product Applications
- Geographic Expansion into Emerging Markets
- Strategic Acquisitions and Partnerships
- Development of new technologies
- Increase adoption in new procedures
Threats
- Intense Competition
- Regulatory Changes and Scrutiny
- Product Liability Litigation
- Economic Downturns Affecting Healthcare Spending
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MDT
- STRY
- BSX
- JNJ
Competitive Landscape
Penumbra's competitive advantage is based on its innovative aspiration technology, which it leverages to compete with larger, more diversified medical device companies. It faces challenges in terms of resources and product breadth.
Major Acquisitions
Mederis AG
- Year: 2016
- Acquisition Price (USD millions): 52
- Strategic Rationale: Expanded Penumbra's neurovascular portfolio with innovative access technology.
Growth Trajectory and Initiatives
Historical Growth: Penumbra has historically demonstrated significant revenue growth, driven by product adoption and market expansion.
Future Projections: Analyst estimates vary, but generally project continued revenue growth in the coming years, based on new product launches and market penetration.
Recent Initiatives: Recent initiatives include expanding sales force, launching new products, and increasing R&D investment.
Summary
Penumbra is a growth-oriented medical device company with a focus on innovative neurovascular and vascular therapies. It has a strong product portfolio and market position, but faces challenges including product recalls and intense competition. The company's growth trajectory is dependent on successful product launches and expansion into new markets. Penumbra should carefully manage its product quality and regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Press Releases, Analyst Reports, Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Penumbra Inc
Exchange NYSE | Headquaters Alameda, CA, United States | ||
IPO Launch date 2015-09-18 | Co-Founder, Chairman, President & CEO Mr. Adam Elsesser J.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4500 | Website https://www.penumbrainc.com |
Full time employees 4500 | Website https://www.penumbrainc.com | ||
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.